Open AccessImidazoline receptor agonist moxonidine and arterial hypertension treatment in women with menopausal metabolic syndrome
Author(s) -
Е. В. Тишина,
В. Б. Мычка,
Yu V Zhernakova,
К. П. Иванов,
С. Н. Толстов,
И Е Чазова
Publication year - 2011
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2011-3-40-46
Subject(s) - moxonidine , medicine , metabolic syndrome , endocrinology , blood pressure , menopause , lipid profile , anthropometry , cholesterol , obesity , agonist , receptor
Aim. To assess the long-term effectiveness and safety of moxonidine (Physiotens®), as antihypertensive treatment in patients with metabolic syndrome (MS), including women with menopausal MS. Material and methods. The study included 274 patients: 203 women (74 %) and 70 men (26 %). Postmenopausal women comprised a separate study subgroup. At baseline and after 24 weeks of moxonidine treatment, all participants underwent anthropometry and the measurement of systolic and diastolic blood pressure (SBP, DBP), lipid and carbohydrate metabolism parameters. Results. Moxonidine therapy was associated with a reduction in SBP and DBP levels. A positive dynamics in the levels of fasting glucose, total cholesterol, low and high-density lipoproteins (LDL, HDL), and triglycerides was observed. The changes in these parameters were similar among postmenopausal women and all study participants. Conclusion. In MS patients, moxonidine improved circadian BP profile, and also demonstrated beneficial effects on carbohydrate and lipid metabolism parameters in women with menopausal MS.